Almeida Neil D, Kuo Cathleen, Schrand Tyler V, Rupp Julia, Madhugiri Venkatesh S, Goulenko Victor, Shekher Rohil, Shah Chirag, Prasad Dheerendra
Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY 14203, USA.
Cancers (Basel). 2024 Oct 21;16(20):3551. doi: 10.3390/cancers16203551.
BACKGROUND/OBJECTIVES: To determine the impact of stereotactic radiosurgery on outcomes of metastatic breast cancer with intracranial metastases.
We systematically searched the PubMed and EMBASE databases for studies published between 1 January 1990 and 1 August 2024. Primary research articles evaluating the outcomes of stereotactic radiosurgery on intracranial metastases from breast cancer were included. Adverse events were defined as leptomeningeal disease, radiation necrosis, seizure, and headache. The pooled estimate was calculated using the DerSimonian and Laird approach.
Sixteen studies encompassing 1228 patients met the inclusion criteria. Our analysis revealed a median survival duration of 13.1 ± 3.8 months and a pooled 1-year overall survival rate of 53.1% after SRS treatment. There was a 29% local recurrence rate at 1 year and a 35% overall distant recurrence rate. In addition, our analysis found a relatively low rate of acute adverse events at 15.5%.
SRS demonstrates promising efficacy and safety in managing intracranial metastases from breast cancer, with a favorable toxicity profile.
背景/目的：确定立体定向放射外科手术对颅内转移的转移性乳腺癌患者预后的影响。
我们系统检索了1990年1月1日至2024年8月1日期间发表在PubMed和EMBASE数据库中的研究。纳入评估立体定向放射外科手术治疗乳腺癌颅内转移瘤疗效的原发性研究文章。不良事件定义为软脑膜疾病、放射性坏死、癫痫发作和头痛。采用DerSimonian和Laird方法计算合并估计值。
16项研究共纳入1228例患者，符合纳入标准。我们的分析显示，立体定向放射外科手术治疗后，中位生存期为13.1±3.8个月，1年总生存率合并为53.1%。1年局部复发率为29%，远处总复发率为35%。此外我们的分析发现急性不良事件发生率相对较低，为15.5%。
立体定向放射外科手术在治疗乳腺癌颅内转移瘤方面显示出良好的疗效和安全性，毒性反应较轻。
Zotero 插件
